These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11737049)

  • 1. New approaches to inducing the death of alloreactive lymphocytes.
    Krams SM
    Clin Exp Immunol; 2001 Dec; 126(3):371-3. PubMed ID: 11737049
    [No Abstract]   [Full Text] [Related]  

  • 2. Cloak and dagger in the avoidance of immune surveillance.
    Pinkoski MJ; Green DR
    Curr Opin Genet Dev; 2000 Feb; 10(1):114-9. PubMed ID: 10679393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction.
    Puppo F; Contini P; Ghio M; Indiveri F
    ScientificWorldJournal; 2002 Feb; 2():421-3. PubMed ID: 12806026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells.
    Zhang HG; Su X; Liu D; Liu W; Yang P; Wang Z; Edwards CK; Bluethmann H; Mountz JD; Zhou T
    J Immunol; 1999 Feb; 162(3):1423-30. PubMed ID: 9973398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A life-raft for death signaling?
    Scheel-Toellner D; Salmon M; Lord JM
    Cancer Biol Ther; 2003; 2(4):396-7. PubMed ID: 14508112
    [No Abstract]   [Full Text] [Related]  

  • 6. DATELINE Aix-les-bains.
    Brunner T; Genestier L
    Cell Death Differ; 1998 Jun; 5(6):539-46. PubMed ID: 10200505
    [No Abstract]   [Full Text] [Related]  

  • 7. Exercise-induced apoptosis of lymphocytes depends on training status.
    Mooren FC; Lechtermann A; Völker K
    Med Sci Sports Exerc; 2004 Sep; 36(9):1476-83. PubMed ID: 15354026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.
    Maher S; Toomey D; Condron C; Bouchier-Hayes D
    Immunol Cell Biol; 2002 Apr; 80(2):131-7. PubMed ID: 11940113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inducible Fas-resistance mediated by IL-4 in activated B cells.
    Foote LC; Marshak-Rothstein A; Rothstein TL
    Ann N Y Acad Sci; 1997 Apr; 815():114-5. PubMed ID: 9186645
    [No Abstract]   [Full Text] [Related]  

  • 11. [Fas, fas ligand, immune tolerance, and cancer: implications in cancer of the colon].
    Berger A; Piqueras B; Pages F; Tartour E; Cugnenc PH; Fridman WH
    Bull Cancer; 1998 Feb; 85(2):129-33. PubMed ID: 9752329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand.
    Shurin GV; Gerein V; Lotze MT; Barksdale EM
    Nat Immun; 1998; 16(5-6):263-74. PubMed ID: 11061594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fas-FasL system and colorectal tumours.
    Rubio CA; Jacobsson B
    J Clin Pathol; 2002 Jul; 55(7):559; author reply 559-60. PubMed ID: 12101215
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulation of fas ligand expression during activation-induced cell death in T cells by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase.
    Zhang J; Gao JX; Salojin K; Shao Q; Grattan M; Meagher C; Laird DW; Delovitch TL
    J Exp Med; 2000 Mar; 191(6):1017-30. PubMed ID: 10727463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells.
    Watanabe D; Suda T; Nagata S
    Int Immunol; 1995 Dec; 7(12):1949-56. PubMed ID: 8746564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity.
    Micheau O; Solary E; Hammann A; Martin F; Dimanche-Boitrel MT
    J Natl Cancer Inst; 1997 Jun; 89(11):783-9. PubMed ID: 9182976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions.
    Sikora J; Dworacki G; Zeromski J
    Nat Immun; 1998; 16(5-6):244-55. PubMed ID: 11061592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis signaling in lymphocytes.
    Scaffidi C; Kirchhoff S; Krammer PH; Peter ME
    Curr Opin Immunol; 1999 Jun; 11(3):277-85. PubMed ID: 10375553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
    Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
    Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E2 inhibits T cell activation-induced apoptosis and Fas-mediated cellular cytotoxicity by blockade of Fas-ligand induction.
    Porter BO; Malek TR
    Eur J Immunol; 1999 Jul; 29(7):2360-5. PubMed ID: 10427999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.